Among them are PD-L1 expression on the tumor as well as tumor-associated immune cells, the presence of a T-cell-inflamed tumor microenvironment signature or interferon-gamma signature [36], or a high mutational burden in the tumor cells as described in the “cancer immunogram” [37]. This evidence concerns the gene IFNG and neoplasm.